• Colorectal Cancer (CRC) case rates are increasingly being the second most deadly cancer with an estimated 1.9 million cases worldwide. The reasons for this are mainly environmental risk factors, lifestyle shifts, and junk food.
  • Early detected Colorectal cancers are highly treatable. Screening is an important part of detecting colorectal cancer, as it helps trace abnormal growth in the colon or rectum.
  • The survival rate of colon cancer patients is as high as 90% if they are detected and treated early.
  • With the help of newly discovered screening tests, people with an average risk of CRC can trace Inflammatory bowel diseases such as ulcerative colitis, a family history of colorectal cancer, the genetic syndrome familial adenomatous polyposis (FAP), and Lynch syndrome etc.

Also Check Top Rated Hospitals

  • CRC Screening methods are based on finding polyps or cancer traces through stool tests, flexible sigmoidoscopy, CT colonography, and colonoscopy. If the test results are positive, a diagnosed colonoscopy test is required to complete the screening process.

  • DNA methylation is an important epigenetic event that occurs during the early stages of oncogenic transformation.

  • Patients between the ages of 40 and 70 who need CRC cancer screening can undergo DNA methylation COLOTECT 3.0.

  • COLOTECT 3.0 is a trademarked sample collection kit. Two sample tubes inside the kit perform two different tests: DNA extraction from stool samples and DNA methylation biomarkers for the detection of colorectal cancer. The other tube carries a faecal immunochemical (FIT) test.

  • According to the researchers and directors of Early Screening Products for Cancer and the BGI Genomics Centered in China, “The early screening of Colorectal Cancer is important and now the COLOTECT sample kit will be used as an accurate and cost-effective stool test for CRC screening in future.

Source - News Medical